produced by recombinant technology
, third-generation B-domain-depleted VIII.
One project in the preclinical stage uses this recombinant technology
to develop supportive therapy to restore the immune system after tumour patients have undergone chemotherapy.
Title: Biosimilars in Emerging Economies - Advanced Recombinant Technology
Platforms and Low Cost Manufacturing Put India and China at a Strategic Advantage in Biosimilar Production
Department of Health and Human Services (HHS), to fund the development of seasonal and pandemic flu vaccines using recombinant technology
This technology utilizes LifeSensors' Small Ubiquitin-like MOdifier (SUMO) system and integration of the recombinant technology
into an automated robotic platform to screen for novel engineered strains of S.
The recombinant technology
used to make Flublok and Panblok is the pandemic solution ; these vaccines can be made safely, accurately and much faster than they could by using other technologies.
Baxter's investigational rVWF concentrate was developed using a plasma- and albumin-free manufacturing method, and represents the largest protein ever produced through recombinant technology
It has been possible to move quickly and safely to develop the H7N9 vaccine because we use modern, proprietary, recombinant technology
that enables us to develop vaccines for potentially deadly viruses without the use of a live disease virus and, therefore, without any risk to personnel.
The application of recombinant technology
to plants has led to major advances in plant biology, allowing production of genetically modified plants that are optimized for yield and/or resistant to pathogens/pesticides.
GBI Research, the leading business intelligence provider, has released its latest report, "Biosimilars in Emerging Economies - Advanced Recombinant Technology
Platforms and Low Cost Manufacturing Put India and China at a Strategic Advantage in Biosimilar Production" that provides key data, information and analysis of the major trends and issues that affect the emerging biosimilars market.
Earlier this year InNexus announced it developed a novel antibody fragment product, IXSCD11a, directed at treatment of psoriasis and produced by recombinant technology
identical to IXS312(VEGF).
If successful in human clinical trials, this advance will usher in the first entirely new way of making therapeutic proteins since the development of recombinant technology
more than 30 years ago, with dramatic implications for both patients and industry.